Combo IVD Market 2025–2033: Innovation and R&D Focus

According to FutureWise analysis, the Combo IVD market in 2025 is US$632.18 million, and is expected to reach US$987.2 million by 2033 at a CAGR of 5.73%. The Combo IVD (In Vitro Diagnostics) market is experiencing significant growth due to the increasing demand for rapid, multi-target diagnostic tests, especially for infectious diseases such as COVID-19, influenza, and RSV. These combination assays improve efficiency, reduce turnaround times, and offer cost-effective testing solutions for both point-of-care and clinical settings. Additionally, advancements in technology, particularly in lateral flow assays and multiplex PCR, are driving the adoption of these methods. Furthermore, the growing focus on early diagnosis and disease surveillance is contributing to the market's expansion.

Combo in vitro diagnostics (IVDs) are medical tools used to measure and analyze biological samples in a controlled environment. These tests are valuable for detecting and monitoring a wide range of medical conditions, including infectious diseases and autoimmune disorders. They are also sometimes utilized to track changes in medication treatments. The rising number of individuals affected by infectious and chronic diseases is driving growth in the in vitro diagnostics industry. Modern workplaces are experiencing an alarming increase in long-term health issues, such as diabetes, cancer, heart disease, and tuberculosis. Additionally, there have been significant rises in cases of infectious diseases, respiratory illnesses, and gastrointestinal problems.

The increasing prevalence of various disorders is expected to boost the demand for diagnostic equipment, which will drive growth in the in vitro diagnostic (IVD) market. Factors such as improved healthcare infrastructure, a rising incidence of chronic health conditions, unmet healthcare needs, and a growing demand for advanced in vitro diagnostic testing are likely to contribute to significant growth in untapped emerging markets. Furthermore, innovations in in vitro diagnostics are pushing the market forward.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Combo IVD Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=15634&type=requestsample

By Test Type

• SARS-CoV-2 Flu A/B Combo Test
• COVID-19, Influenza A/B, RSV Combo test
• COVID-19 IgM/IgG Combo Test
• HIV-1/2 Ag/Ab Combo Test
• HIV/Syphilis Ab Combo Test
• HIV, HBsAg, HCV & Syphilis Combo
• hCG Combo Test
• Thrombophilia Detection Combo Test
• Other Test Types

By Testing

• Rapid testing
• Point of care testing

By End-User

• Diagnostics centres 
• Hospitals
• Homecare setting   
• Other End-Users

By Channel

• Over-the-Counter
• Laboratory based

By Sample Type

• Orals and Nasal Swabs
• Human Serum
• Whole Blood
• Other Sample Types

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Combo IVD Market:

• DRG International Inc.
• Roche
• Becton, Dickinson and Company
• DiaCarta Inc
• Danaher Corporation
• Abbott
• bioMérieux SA4
• Bio-Rad Laboratories
• Alpha IVD Srl
• Sysmex Corporation
• BioGX BV
• Thermo Fisher Scientific Inc.
• Megna Health Inc
• CTK Biotech, Inc.
• Biopanda Reagents Ltd

Recent developments by key players in the Combo IVD Market:

Bio-Rad Laboratories:

• In January 2023, we launched the CFX Opus Deepwell Dx Real-Time PCR System. This system is FDA-cleared and compliant with EU IVD standards, offering high-throughput molecular testing suitable for combination assays.

Becton, Dickinson & Company (BD):

• In June 2022, the BD MAX™ Respiratory Viral Panel (RVP) received CE marking. This multiplex PCR assay can detect RSV, SARS-CoV-2, and Influenza A/B from a single sample, streamlining diagnostics for respiratory infections.

Thermo Fisher Scientific Inc:

• In December 2023, we released the KingFisher Apex Dx automated system and the MagMAX Dx Viral/Pathogen NA Kit, both of which are IVD-approved, to enhance sample preparation for multiplex pathogen detection.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=15634&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Combo IVD Market By Test Type, By Testing, By End-User, By Channel, By Sample Type and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]